Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
991 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02482311 | Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | completed | Phase 1 | 92 | AstraZenecaINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT02610075 | Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. | completed | Phase 1 | 62 | AstraZenecaINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04381494 |
| Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) |
| terminated |
| Phase 4 |
| 40 |
| AstraZenecaINDUSTRY |
| 1 |
| Jun 22, 2023 |
| clinicaltrials |
| NCT02740985 | A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 313 | AstraZenecaINDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT04495127 | Selumetinib Paediatric NF1 Japan Study | completed | Phase 1 | 12 | AstraZenecaINDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04962880 | HRR Prevalence in LatAm PROSPECT Study(PROSPECT) | completed | — | 388 | AstraZenecaINDUSTRY | 7 | Apr 14, 2023 | clinicaltrials |
| NCT02733601 | Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria(BreCaReAl) | completed | — | 1,500 | AstraZenecaINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03590938 | Lynparza Breast Cancer Clinical Experience Investigation | completed | — | 111 | AstraZenecaINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03463525 | Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases(ODIN-BM) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
| NCT01625286 | Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients(BEECH) | completed | Phase 1 / Phase 2 | 148 | AstraZenecaINDUSTRY | 11 | Jan 18, 2023 | clinicaltrials |
| NCT03286842 | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. | completed | Phase 3 | 256 | AstraZenecaINDUSTRY | 15 | Jan 17, 2023 | clinicaltrials |
| NCT05551897 | A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole | completed | Phase 1 | 14 | AstraZenecaINDUSTRY | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03084471 | An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.(STRONG) | completed | Phase 3 | 867 | AstraZenecaINDUSTRY | 8 | Dec 22, 2022 | clinicaltrials |
| NCT03971110 | A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. | terminated | Phase 4 | 9 | AstraZenecaINDUSTRY | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05345678 | Himalaya Early Access Program | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT02908750 | Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | completed | Phase 1 | 24 | AstraZenecaINDUSTRY | 3 | Nov 14, 2022 | clinicaltrials |
| NCT03106987 | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.(OReO) | completed | Phase 3 | 220 | AstraZenecaINDUSTRY | 11 | Oct 7, 2022 | clinicaltrials |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | terminated | Phase 1 | 70 | AstraZenecaINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02588105 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer(AToM) | completed | Phase 1 | 84 | AstraZenecaINDUSTRY | 4 | Sep 19, 2022 | clinicaltrials |
| NCT04959266 | A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | terminated | Phase 1 | 5 | AstraZenecaINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT02476968 | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer(ORZORA) | completed | Phase 4 | 181 | AstraZenecaINDUSTRY | 8 | Sep 10, 2022 | clinicaltrials |
| NCT05008913 | Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib(ADME) | terminated | Phase 1 | 2 | AstraZenecaINDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04949425 | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | terminated | Phase 1 | 3 | AstraZenecaINDUSTRY | 2 | Sep 2, 2022 | clinicaltrials |
| NCT00819221 | AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 2 | Aug 30, 2022 | clinicaltrials |
| NCT04742036 | Capivasertib China PK Study | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04462952 | Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03505307 | Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) | completed | — | 846 | AstraZenecaINDUSTRY | 0 | Jun 1, 2022 | clinicaltrials |
| NCT04944771 | Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants | completed | Phase 1 | 48 | AstraZenecaINDUSTRY | 1 | May 9, 2022 | clinicaltrials |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | completed | Phase 2 | 272 | AstraZenecaINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | terminated | Phase 1 | 50 | AstraZenecaINDUSTRY | 2 | Apr 5, 2022 | clinicaltrials |
| NCT02932345 | Gefitinib Long-term Survivor Study | terminated | — | 59 | AstraZenecaINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT02725892 | National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria(LuCaReAl) | completed | — | 897 | AstraZenecaINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03583463 | ALEXANDRIA Study Egypt | completed | — | 436 | AstraZenecaINDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT04425200 | Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting(ZENSHIN) | completed | — | 205 | AstraZenecaINDUSTRY | 1 | Dec 7, 2021 | clinicaltrials |
| NCT02474355 | Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC(ASTRIS) | completed | Phase 3 | 3,017 | AstraZenecaINDUSTRY | 16 | Nov 11, 2021 | clinicaltrials |
| NCT04222465 | Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients(CHRISTELLE) | completed | — | 207 | AstraZenecaINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT04460768 | An INternational Frontline Ovarian Cancer Real World Management Study(INFORM) | completed | — | 989 | AstraZenecaINDUSTRY | 3 | Sep 27, 2021 | clinicaltrials |
| NCT03219970 | Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting. | completed | — | 156 | AstraZenecaINDUSTRY | 1 | Sep 14, 2021 | clinicaltrials |
| NCT02780713 | A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects(PK) | completed | Phase 1 | 14 | AstraZenecaINDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04187456 | A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body | completed | Phase 1 | 14 | AstraZenecaINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT02978482 | A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies | completed | Phase 1 | 26 | AstraZenecaINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials